期刊
NEUROBIOLOGY OF AGING
卷 33, 期 2, 页码 215-225出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2010.03.011
关键词
Alzheimer's disease; Amyloid plaques; Amyloidosis; Cognition; Dementia severity; Fluorodeoxyglucose; Glucose metabolism; Pittsburgh Compound-B
资金
- National Institute on Aging [NIA K23-AG031861, NIA AG027859, NIA P01-AG1972403, P50-AG023501]
- Alzheimer's Association [NIRG-07-59422, ZEN-08-87090]
- John Douglas French Alzheimer's Foundation
The authors investigated relationships between glucose metabolism, amyloid load, and measures of cognitive and functional impairment in Alzheimer's disease (AD). Patients meeting criteria for probable AD underwent C-11-labeled Pittsburgh Compound-B ([C-11]PIB) and 18F-fluorodeoxyglucose ([F-18]FDG) positron emission tomography (PET) imaging and were assessed on a set of clinical measures. The Pittsburgh Compound-B (PIB) Distribution volume ratios and fluorodeoxyglucose (FDG) scans were spatially normalized and average PIB counts from regions-of-interest (ROI) were used to compute a measure of global PIB uptake. Separate voxel-wise regressions explored local and global relationships between metabolism, amyloid burden, and clinical measures. Regressions reflected cognitive domains assessed by individual measures, with visuospatial tests associated with more posterior metabolism, and language tests associated with metabolism in the left hemisphere. Correlating regional FDG uptake with these measures confirmed these findings. In contrast, no correlations were found between either voxel-wise or regional PIB uptake and any of the clinical measures. Finally, there were no associations between regional PIB and FDG uptake. We conclude that regional and global amyloid burden does not correlate with clinical status or glucose metabolism in AD. (C) 2012 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据